TrialJCO global oncology2024

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial.

Naveen Reddy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.